• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
176667 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  4 n* \& J4 N0 n1 m; u
9 m5 c+ e5 t) {3 n

( p% r3 b7 [' A" sSub-category:+ _8 O, |/ K, Y5 u' Q  M1 `0 d
Molecular Targets
  `3 d& u8 ]7 ~$ j3 V0 @8 @2 f& b" W. Q( d/ Q& F- d4 X
, b5 z$ {3 D. v) L, q) F
Category:
3 F2 Y; O1 U& a6 R; H" VTumor Biology
9 V6 N6 l& F- g% N; L# O3 |% f/ r9 P7 x( A$ f
: ^4 ^" S! j; O. ~" Q
Meeting:5 E5 C6 c6 X0 K$ X+ }
2011 ASCO Annual Meeting 0 r+ N2 Z0 y* W! P* y9 q

" t7 _% v$ @5 f
8 q: b3 E4 k' ~' }. R5 i( dSession Type and Session Title:* u% j8 B$ _9 b2 Z0 o- r  @4 l) j$ m
Poster Discussion Session, Tumor Biology
& g' Q% b% q# z9 Z" g1 P7 ~& X2 a" S: U6 S) T

8 g/ m3 i  S3 |7 ^& u1 W' O( bAbstract No:" z8 ?! ]6 m2 k
10517 . c9 h) O& W3 j4 w4 a4 d! m6 K
0 z0 g  p; b- i  X* l0 M
* P4 m/ `: k' p% F( ]% L( ?
Citation:, Q9 a; u4 u, w$ J" Y6 T  n  C
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. D; y2 }# G9 @
9 p  S! m8 X- B  d2 w' l' S; z5 G5 a3 O/ N* l
Author(s):$ ^' C7 J: M* Z- c* G8 r5 S5 m0 ?# ?
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ ^$ ^% g1 H- P! p" R7 _' P! z4 J! g2 C( C1 t% M9 e
) L8 P6 Y8 g2 j, @

- Z4 [! D' Q/ ~" ^: ?Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.9 X+ u: h1 w4 r. K
5 l. T' d4 ~7 u; @2 X  i1 o8 y
Abstract Disclosures
8 u$ C0 F! Q7 v3 V/ |, p% U1 x
9 U$ @' \+ s- R/ u) c0 OAbstract:' N/ h' J. e+ x, N" e+ A+ s( S

& L# z3 a3 ^2 N5 J, V1 w
; p8 m# u/ ]0 A% Q) P3 g7 c6 LBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- f, D2 c: E3 ?# Q: `, t9 v2 n

- @. A) v7 N. v' i  }7 D0 K
4 y& x5 p, ^7 `* `2 G2 O$ M" J6 ~" q
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
% R0 F7 c+ o5 ?# ^8 Z没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

. K6 @6 y" c) z# |; }化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ' h  I1 F2 X9 m  f/ x+ e
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
: @7 |( z% B# p$ {" LALK一个指标医院要900多 ...

0 i3 g$ Q2 v" M% R4 `平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?) q+ {6 K+ H) U

( w  H, b- R8 i) v! ?8 J现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表